Register for updates about Emgality

Learn more about Emgality when you register with us. Please enter your information below.

You are now registering to receive information about Emgality intended for healthcare providers. By submitting the information requested below, you certify that you are a healthcare provider. Lilly’s intent is to only provide information to healthcare providers.


IMPORTANT


The information you provide in this form will be used in accordance with the Lilly Privacy Statement. The information you provide to Lilly may also be used for marketing purposes. Also, any information or suggestions you provide regarding the content of any Lilly website, published document, or product will be handled in accordance with our Copyright Statement.

By submitting this registration form, I agree that my use of this website and any emails I receive in response to this registration is subject to this website’s Terms of Use, Privacy Statement, and Copyright Policy. I have read the Terms of Use, Privacy Statement, and Copyright Policy contained on this website and agree to be bound by such terms.


Indications and Important Safety Information
Indications

Emgality is a calcitonin gene-related peptide (CGRP) antagonist indicated for the preventive treatment of migraine in adults.

Important Safety Information

CONTRAINDICATIONS
Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.


WARNINGS AND PRECAUTIONS
Hypersensitivity Reactions
Hypersensitivity reactions (e.g., rash, urticaria, and dyspnea) have been reported with Emgality in clinical studies. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.


ADVERSE REACTIONS
The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in Emgality clinical studies were injection site reactions.


Emgality is available by prescription only.


Please see Full Prescribing Information, including Patient Information for Emgality. See Instructions for Use included with the pen and prefilled syringe.


GZ HCP ISI 27SEP2018